340binformed.org

Your Free Source for 340B News and Commentary

  • About us
  • Advertise
  • Contact
  • 340B Health

Hospitals Protest Genentech’s Deeming Cancer Drugs as Specialty Meds

State Medicaid chiefs, meanwhile, say Sovaldi might need federal price controls
 

Print Article

October 30, 2014—Hospital groups are protesting Genentech’s decision to make them buy three very expensive and much-used cancer drugs exclusively through specialty distributors, saying the change is raising their costs and potentially compromising patient care without enhancing patient safety or supply-chain security.  


You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register.    Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

LATEST ARTICLES DELIVERED

Get new article alerts via email.

This field is required.

Check your inbox or spam folder now to confirm your subscription.

FOLLOW | SHARE | LIKE

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

340B Health Twitter

Twitter feed is not available at the moment.

RSS feed: 340B Employed 340B Employed

  • 340B Program Compliance Analyst Certified | UNC Health November 17, 2026
  • 340B Program Compliance Analyst Certified | UNC Health November 17, 2026
  • 340B Program Specialist | Vail Health November 17, 2026
  • Pharmacy Manager, 340B Program | Tufts Medical Center November 11, 2026
  • 340B Program Pharmacy Manager | Allies for Health + Wellbeing November 10, 2026

Copyright © 2026 · 340B Health